CTLA4 and cancer: KMPlot analysis showed that cancer patients with high MNAI had significantly prolonged PFS after anti-PD-1 (p = 0.00021, Figure 6A) and anti-CTLA-4 (p = 0.00071, Figure 6B) treatment but not after anti-PD-L1 treatment (p = 0.22, Figure 6C).